OBJECTIVE To identify clinicopathologic factors which predictlymph node metastases (LNM) in early mucinous adenocarcinomapatients, and to further explore the possibility of using minimallyinvasive treatment for patien...OBJECTIVE To identify clinicopathologic factors which predictlymph node metastases (LNM) in early mucinous adenocarcinomapatients, and to further explore the possibility of using minimallyinvasive treatment for patients with the disease.METHODS Data was collected from 38 patients with earlymucinous adenocarcinoma who were surgically treated, and theassociation between clinicopathologic factors and the presenceof LNM was retrospectively analyzed using univariate andmultivariate logistic regression analysis.RESULTS Tumor size greater than 2.0 cm, the developmentof submucosal invasion, and the presence of lymphatic vesselinvolvement (LVI) were confirmed through univariate analysis ashaving a significant association with LNM and were consideredto be significant and independent risk factors for LNM throughmultivariate analysis.CONCLUSION Tumor size > 2.0 cm, the development ofsubmucosal invasion, and the presence of LVI are independentpredictive factors for LNM in early mucinous adenocarcinoma.Minimally invasive treatment may be an effective treatment forintramucosal early mucinous adenocarcinoma when the tumorsize is 2.0 cm or less, and if LVI has not occurred, as confirmed bypostoperative histologic examination.展开更多
The incidence of esophageal adenocarcinoma(EAC)has markedly increased in the United States over the last few decades.Barrett’s esophagus(BE)is the most significant known risk factor for this malignancy.Theoretically,...The incidence of esophageal adenocarcinoma(EAC)has markedly increased in the United States over the last few decades.Barrett’s esophagus(BE)is the most significant known risk factor for this malignancy.Theoretically,screening and treating early BE should help prevent EAC but the exact incidence of BE and its progression to EAC is not entirely known and costeffectiveness studies for Barrett’s screening are lacking.Over the last few years,there have been major advances in our understanding of the epidemiology,pathogenesis and endoscopic management of BE.These developments focus on early recognition of advanced histology and endoscopic treatment of high-grade dysplasia.Advanced resection techniques now enable us to endoscopically treat early esophageal cancer.In this review,we will discuss these recent advances in diagnosis and treatment of Barrett’s esophagus and early esophageal adenocarcinoma.展开更多
文摘OBJECTIVE To identify clinicopathologic factors which predictlymph node metastases (LNM) in early mucinous adenocarcinomapatients, and to further explore the possibility of using minimallyinvasive treatment for patients with the disease.METHODS Data was collected from 38 patients with earlymucinous adenocarcinoma who were surgically treated, and theassociation between clinicopathologic factors and the presenceof LNM was retrospectively analyzed using univariate andmultivariate logistic regression analysis.RESULTS Tumor size greater than 2.0 cm, the developmentof submucosal invasion, and the presence of lymphatic vesselinvolvement (LVI) were confirmed through univariate analysis ashaving a significant association with LNM and were consideredto be significant and independent risk factors for LNM throughmultivariate analysis.CONCLUSION Tumor size > 2.0 cm, the development ofsubmucosal invasion, and the presence of LVI are independentpredictive factors for LNM in early mucinous adenocarcinoma.Minimally invasive treatment may be an effective treatment forintramucosal early mucinous adenocarcinoma when the tumorsize is 2.0 cm or less, and if LVI has not occurred, as confirmed bypostoperative histologic examination.
文摘The incidence of esophageal adenocarcinoma(EAC)has markedly increased in the United States over the last few decades.Barrett’s esophagus(BE)is the most significant known risk factor for this malignancy.Theoretically,screening and treating early BE should help prevent EAC but the exact incidence of BE and its progression to EAC is not entirely known and costeffectiveness studies for Barrett’s screening are lacking.Over the last few years,there have been major advances in our understanding of the epidemiology,pathogenesis and endoscopic management of BE.These developments focus on early recognition of advanced histology and endoscopic treatment of high-grade dysplasia.Advanced resection techniques now enable us to endoscopically treat early esophageal cancer.In this review,we will discuss these recent advances in diagnosis and treatment of Barrett’s esophagus and early esophageal adenocarcinoma.
